REMED
A New Era of Non-Invasive Medicine with Electroceuticals

Electroceuticals are becoming the pulse of the new health era.

The concept of using electronic signals to treat ailments is not new, with spinal cord stimulation, cochlear implants, and pacemakers already available. The hope with electroceuticals is that by miniaturizing electrode devices and attaching them to strategic nerves, the brain can be fed alternate messages to heal itself.

Electroceuticals are still in the early stages of development, and scientific opinion is divided on their efficacy, but various pharmaceutical and technology companies are betting on their success.

One of them is REMED.

REMED is a specialist focused on leveraging the benefits of electroceuticals to cure intractable body aches and mental health issues like anxiety and depression. Since its inception, REMED has been researching heavily on brain stimulation solutions. The outcome is its FDA-approved products that non-invasively stimulate affected nerves with a magnetic field of varying frequencies up to 3.0 Tesla.

The strength of its electroceuticals comes from its transcranial magnetic stimulation (TMS) technology. Its TMS electroceutical, TAMAS, comes with an electromagnetic coil that produces a magnetic field as strong as 0.5 to 3.0 Tesla. A more compact version of the TMS, Brain Stim, uses a magnetic flux of 0.5 to 2.5 Tesla to stimulate the nerve cells responsible for emotional processing and successfully alleviate depressive symptoms.

REMED uses neuromagnetic technology for pain management as well. Its Neuro Magnetic Stimulator (NMS) has a similar anatomy to TMS but with a circular transducer. The strong magnetic field applied to the pain area passes through the skin and fat layer.

It then stimulates nerve fibers that regulate blood flow to the damaged tissues and improves the inflammatory processes and metabolism, enhancing the healing process.

The products are a league above common antidepressants, electro-convulsive therapies (ECT), and painkillers in terms of side effects and course of treatment. While ECT causes cognitive side effects, oral drugs cause insomnia and nausea, and take months to show improvement. REMED’s solutions cause minimal side effects and show easing symptoms after a single or more sessions depending on the patients.

REMED’s spectrum of products goes beyond neuro-stimulators. Its Core muscle Strengthening Magnetic Stimulator (CSMS), for instance, works non-invasively through the skin to tighten and strengthen loose muscles. It helps in aesthetic treatments, improves postpartum urinary incontinence in women, and assists in regaining motor skills after accidents and surgeries.

Its NMS helped a woman walk again after an accident. In another instance, REMED’s TMS device rejuvenated a patient with extreme anxiety. Similar successful use cases prompt REMED to globally expand its solutions. In this regard, it is forming a joint venture company in Japan and the U.S. respectively by 2022 and 2023.

The company is always keen on ensuring quality. The team conducts regular internal meetings on new product development and discusses innovative features and designs to make its products more convenient and comfortable.

“We invest 15 to 20 percent of our annual sales in research and development activities. We consider R&D a key aspect that develops our company,” states Eun-Hyun Charles Koh, CEO of REMED.
More importantly, all of its products are physician-assured, which adds to its credibility.

The development of electroceuticals can be attributed to advancing micro technology, but its practical use requires an efficient service provider like REMED. Its customer-friendly and patient-focused missions drive product development, making REMED a frontrunner among electroceutical manufacturers.